Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Other factors also contribute to replication
2021-08-11

Other factors also contribute to replication fork progression in DNA damage conditions. For instance, the cullin Rtt101 has a role in fork movement through alkylated DNA, probably associated to a damage tolerance mechanism [52], and TORC signaling is also important for fork progression in response t
-
Nitric oxide NO is synthesized by conversion of
2021-08-11

Nitric oxide (NO) is synthesized by conversion of the l-arginine to NO and l-citrulline through reaction which is catalyzed by nitric oxide synthetase (NOS) (Knowles and Moncada, 1994). NO as an important molecule not only play a role as second messenger but also binds to cytochrome c oxidase and de
-
Nitric oxide NO is synthesized by conversion of
2021-08-11

Nitric oxide (NO) is synthesized by conversion of the l-arginine to NO and l-citrulline through reaction which is catalyzed by nitric oxide synthetase (NOS) (Knowles and Moncada, 1994). NO as an important molecule not only play a role as second messenger but also binds to cytochrome c oxidase and de
-
Overall the DDR kinase domain has
2021-08-11

Overall, the DDR1 kinase domain has a typical kinase domain structure and adequate sequence and/or structure similarity with other kinase domains, as shown in Fig. 2, which allow homology modeling of the active and inactive conformations. In addition to conformational changes to the activation loop
-
br Chagas disease Chagas disease an
2021-08-10

Chagas disease Chagas disease, an NTD caused by the protozoan Trypanosoma cruzi, affects 8–10 million people globally. More than 10,000 deaths are caused by the disease each year, and nearly 70 million people are susceptible to infection (Manne-Goehler, Umeh, Montgomery, & Wirtz, 2016). Chagas di
-
br Introduction Sphingolipids are ubiquitous membrane compon
2021-08-10

Introduction Sphingolipids are ubiquitous membrane components of all eukaryotic cells belonging to a group of complex lipids. The basic structure of sphingolipids is composed of a sphingoid long chain base (LCB) linked to a fatty chemicals via an amide bond to form a ceramide [1]. In animals, sp
-
Interaction between neutrophils and ECs represents the
2021-08-10

Interaction between neutrophils and ECs represents the first step of the cellular phase of the inflammatory response, and provide the best condition for the transfer of the PMNL-derived LTA4 to the ECs, leading to the transcellular formation of cysteinyl-LTs. It is intriguing therefore to think that
-
A variety of fused membered ring chemotypes have
2021-08-10

A variety of fused 6–5-membered ring chemotypes have arisen such as 7-azaindole acetic acids, benzimidazolyl acetic acids, spiro-indolinone acetic acids, and indolizine acetic acids, however, to the best of our knowledge, fused 5,5-membered ring systems have not been reported. Prostaglandin D (PG
-
Autophagy is a dynamic process that
2021-08-10

Autophagy is a dynamic process that primarily involves autophagosome formatting and lysosomal degradation, and these processes are controlled by autophagy-related genes (Atg) (Klionsky et al., 2012). The related protein SQSTM1/p62 (sequestosome 1) importantly serves as a signalling director in sever
-
br Acknowledgements This work was supported by
2021-08-10

Acknowledgements This work was supported by the European Committee Fifth Framework Project QLK5-1999-01360. We are grateful to Dr. T.T. Hoang for the provision of plasmids pEX18Tc, pPS858 and pFLP2, Prof. B.L. Wanner for providing us with the plasmid pKD4 and related strains, and Prof. P. Soucail
-
br Third trimester crossing the threshold to immunocompetenc
2021-08-10

Third trimester – crossing the threshold to immunocompetence Summary Regrettably, studies on the fetal immune system have yet to yield practical results. While it is becoming apparent that the fetal immune response plays a role in determining the outcome of congenital CMV infection, we still l
-
Most of the data indicating that the six
2021-08-09

Most of the data indicating that the six-ankyrin repeat domain-containing Asb genes drive compartment expansion come from zebrafish and concern Asb11. However, there is evidence to suggest that these data can be expanded to the entire vertebrate phylum and to all six-ankyrin repeat domain-containing
-
SIRT is a representative member
2021-08-09

SIRT1 is a representative member of Sirtuins, which is a family of highly conserved NAD+-dependent class III histone deacetylases. SIRT1 deacetylates plentiful nonhistone protein substrates [Atgs, Foxo1, Foxo3, PGC-1α, NF-kB, E2F1 and p53] (Conrad et al., 2016; Gu et al., 2016; Tu et al., 2018) to p
-
Addressing whether impaired activation of D
2021-08-09

Addressing whether impaired activation of D1 and D2 receptors regulates memory capacity is relevant for all human pathologies that lead to reduced activation of these Ertapenem sodium salt pathways, such as ageing [39], certain genetic polymorphisms [40] and neurodegenerative disorders. In this stud
-
We have compared the potency of
2021-08-09

We have compared the potency of a series of DNA-directed alkylating agents, including N-mustard-acridine, N-mustard-quinoline, and N-mustard-quinazoline conjugates previously synthesized in our laboratory [7], [13], and currently used drugs (oxaliplatin, cisplatin, or 5-FU) for the treatment of CRC
15836 records 583/1056 page Previous Next First page 上5页 581582583584585 下5页 Last page